Who: Sanofi/Scribe Therapeutics
What: Sanofi is partnering with the next-generation gene editing firm founded by Jennifer Doudna, one of the inventors of CRISPR-Cas9 genome editing, to advance its work on engineered
Sanofi ThiNKs Scribe’s CRISPR Approach Can Advance Its NK Cell Therapy Goals
Deal Snapshot: CRISPR-Cas9 co-inventor Jennifer Doudna-founded gene-editing firm inks its second large collaboration, teaming with Sanofi on off-the-shelf natural killer cell therapies for cancer.
